Goldman Sachs Reports on Alexion Pharmaceuticals (ALXN)

Goldman Sachs commented on Alexion Pharmaceuticals ALXN in a report released yesterday. In the report, Goldman Sachs downgraded the company, but remained somewhat positive. Goldman Sachs writes, “We remove ALXN from our Conviction Buy list and replace it with MAKO Surgical, but we maintain our Buy rating. We continue to see ALXN as one of the best stories to own in healthcare, but one which now has less upside after delivering on recent catalysts to our unchanged price target of $112. We continue to view it as a core holding with solid long term growth. The stock has risen 32% since we added the stock to the CL list on 11/4/10 vs. 9% for the S&P 500 and 85% over the past 12 months vs. 17% for the S&P.” Goldman Sachs presently has a Buy rating on Alexion and a price target of $112.00. Shares of the company closed the trading day yesterday at $96.32, down from $99.42 at open.